Heart Failure – Comprehensive Study Notes

Heart Failure: Comprehensive Study Notes

  • Definition and overview

    • Heart failure (HF) is the inability of the heart to pump sufficient blood to meet the tissues’ needs for oxygen and nutrients. It is a syndrome characterized by fluid overload or inadequate tissue perfusion.
    • HF indicates myocardial disease, with problems in either contraction (systolic failure) or filling (diastolic failure).
    • Some cases are reversible, but most HF is a progressive, lifelong disorder managed with lifestyle changes and medications.
    • Key distinction: HF can involve systolic dysfunction, diastolic dysfunction, or both.

  • Left-sided vs. right-sided heart failure

    • Left-sided HF:
    • Primary pulmonary symptoms: dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND).
    • Pulmonary congestion can lead to cough and crackles; hypoxemia may occur.
    • Right-sided HF:
    • Increased venous pressure leading to systemic congestion: edema (peripheral and ascites), enlarged liver and spleen, jugular venous distention (JVD).
    • Fatigue, anorexia, GI distress, weight gain, and dependent edema.
    • Note: Some sources summarize as left-sided (pulmonary symptoms) and right-sided (systemic venous congestion).

  • Risk factors and contributing factors

    • Pre-existing conditions that damage the heart:
    • Coronary heart disease, hypertension, valvular heart disease, infections, chemotherapy-induced heart damage, pregnancy-related heart failure, and situations with persistently increased heart rate.
    • HF can develop from unknown causes in some cases.
    • Unhealthy behaviors contributing to risk:
    • Sedentary lifestyle; obesity increases risk (e.g., obese women have ~50% greater risk of heart failure vs women of normal weight).
    • Sodium and fluid considerations:
    • Excess sodium and fluid intake can lead to fluid buildup and swelling.
    • Dietary guidance: eliminate or reduce added salt; limit fluid intake to 2 liters/day2\ \text{liters/day}.
    • Substance risks:
    • Alcohol and drug abuse are risk factors.

  • Diagnostic assessment and biomarkers

    • Diagnostic/Assessment tools and tests:
    • Echocardiogram (to assess structure and function) and ejection fraction (EF).
    • ECG and comprehensive metabolic panel (electrolytes, BUN & creatinine), liver function tests (LFT), thyroid-stimulating hormone (TSH), CBC, chest X-ray, cardiac enzymes, BNP.
    • BNP interpretations (thresholds):
    • BNP<100\text{BNP} < 100 implies no HF; BNP>400\text{BNP} > 400 suggests HF. BNP increases with worsening HF.
    • Additional considerations: BNP is a marker of fluid overload and ventricular strain; higher BNP correlates with severity.

  • Functional status and risk screening

    • A brief functional assessment questionnaire evaluates daily living activities and exercise tolerance:
    • Are you able to shower and dress without stopping or becoming short of breath?
    • Have you been admitted more than once in the last 12 months for HF symptoms?
    • Are you able to walk a city block (≈500 feet) without stopping or becoming short of breath?
    • Are you able to climb a flight of stairs or carry groceries without stopping or breathlessness?
    • Have you been unable to tolerate HF medications (e.g., beta-blockers or ACE inhibitors)?
    • If you’re on HF medications, have symptoms improved or worsened?
    • If any answer is NO to any question, or YES to any question, further evaluation or action may be indicated.

  • Symptoms and clinical presentation (congestion vs poor perfusion)

    • Congestion signs/symptoms:
    • Dyspnea, orthopnea, PND, cough (recumbent or exertional), pulmonary crackles, rapid weight gain, dependent edema, abdominal bloating or discomfort, ascites, JVD, sleep disturbance (anxiety or air hunger), fatigue.
    • Poor perfusion/low cardiac output signs/symptoms:
    • Decreased exercise tolerance, muscle wasting/weakness, anorexia/nausea, unexplained weight loss, lightheadedness or dizziness, confusion or altered mental status, resting tachycardia, daytime oliguria with recumbent nocturia, cool or vasoconstricted extremities, pallor or cyanosis.

  • Nursing care priorities and monitoring

    • Daily weights and intake/output (I&O) to monitor fluid status.
    • Assess for shortness of breath and dyspnea on exertion; administer oxygen as needed.
    • Monitor vital signs and respond to hypotension or hypoxia.
    • Positioning: high-Fowler’s position to maximize ventilation when appropriate.
    • Review laboratory results and monitor response to medications.
    • Encourage bed rest until stable, then energy-conserving strategies for ADLs.
    • Sodium restriction and bedside education on low-sodium diet.

  • Treatment goals

    • Improve cardiac function with medications.
    • Reduce symptoms and improve quality of life.
    • Stabilize HF to decrease hospitalizations and delay progression.
    • Promote a heart-healthy lifestyle and extend life expectancy through optimized management.

  • Pharmacologic management overview

    • ACE inhibitors (ACEIs): e.g., lisinopril, enalapril
    • Mechanism: vasodilation, diuresis, reduced afterload; monitor for hypotension, hyperkalemia, renal function changes; may cause cough.
    • Angiotensin II receptor blockers (ARBs): e.g., valsartan, losartan
    • Use as an alternative to ACEIs; similar mechanism and effects.
    • Hydralazine and isosorbide dinitrate: alternative to ACEIs/ARBs.
    • Beta-blockers: e.g., carvedilol, bisoprolol, metoprolol
    • Add-on therapy to ACE inhibitors; effects may take weeks; caution in asthma.
    • Diuretics: reduce fluid volume; monitor electrolytes.
    • Digitalis (digoxin): improves contractility; monitor for toxicity, especially with hypokalemia.
    • IV inotropes for acute decompensated HF: Milrinone (milrinone lactate) and Dobutamine
    • Milrinone: decreases preload and afterload; may cause hypotension and dysrhythmias.
    • Dobutamine: increases contractility and renal perfusion (mainly for LV dysfunction).
    • Other medications and considerations:
    • Antihypertensives, anticoagulants, statins, antiarrhythmias.
    • A note/question: Which class of medications should HF patients avoid? (Content not explicitly provided; consult current guidelines.)

  • In-depth look at diuretic therapy (Chart 25-2 guidance)

    • Prior to diuretic administration:
    • Check electrolytes (potassium, sodium, magnesium).
    • Check for volume depletion indicators (orthostatic hypotension, lightheadedness, dizziness).
    • Timing and administration:
    • Administer early in the day to reduce nocturia; align with patient lifestyle.
    • Monitoring and response assessment:
    • Monitor urine output, daily weights, I&O, and blood pressure for orthostatic changes.
    • Monitor electrolytes (potassium, magnesium, sodium) and adjust as needed; monitor for hyperkalemia with potassium-sparing diuretics.
    • Monitor creatinine for possible diuretic-induced renal dysfunction.
    • Monitor uric acid level and signs of gout.
    • Assess lungs and edema to evaluate diuretic response.
    • Be vigilant for arrhythmias as an adverse reaction.
    • Patient management:
    • Help manage urinary frequency and urgency associated with diuretic therapy.

  • Other supportive and interventional options

    • Nutritional therapy and fluid management; sleep disorder management; supplemental oxygen as needed.
    • Procedural and surgical interventions as indicated by HF severity and etiology.
    • Cardiac resynchronization therapy (CRT): device pacing both ventricles to improve synchrony
    • How it works: leads in right atrium and right ventricle; additional lead via coronary sinus to a lateral wall of the left ventricle.
    • Exercise and activity recommendations as part of a comprehensive lifestyle plan.

  • Patient education and self-management

    • Key teaching points:
    • Medication adherence and compliance.
    • Diet: low sodium and fluid restriction; limit alcohol; avoid tobacco.
    • Weight monitoring and edema/swelling assessment; notify the clinician for weight gain (e.g., gain of >2 lb/day or >5 lb/week).
    • Activity: balance activity with rest; plan periods of rest.
    • Exercise program guidance (Chart 25-3 Health Promotion):
    • Consult with primary provider for personalized exercise plan.
    • Begin with low-impact activities (e.g., walking).
    • Start with warm-up, gradually build to ~30 minutes; include cool-down.
    • Avoid extreme heat, cold, or humidity; wait 2 hours after eating before exercising.
    • Ability to talk during activity; stop if severe dyspnea, chest pain, or dizziness occurs.
    • Education evaluation and outcomes (Education Evaluation):
    • Understand medication administration, restrict sodium to 2 g/day, engage in exercise, avoid alcohol & smoking.
    • Daily weight and symptom monitoring; know when to notify the healthcare provider.
    • Completion targets for patients and caregivers:
    • Recognize HF as a chronic disease manageable with meds and self-management.
    • Understand impact on function, ADLs/IADLs, roles, relationships, and spirituality.
    • Know medication names, doses, side effects, frequency, and schedule; administer meds as prescribed.
    • Monitor effects of meds on breath, edema; watch for orthostatic hypotension and educate prevention.
    • Daily weight in a consistent manner; sodium restriction and dietary adaptations.
    • Avoid excessive eating/drinking, participate in prescribed activity program, conserve energy, and avoid extreme temperatures.
    • Develop stress management strategies; avoid tobacco, limit alcohol; engage in social activities.
    • Identify community resources for support; know how to contact providers for questions/complications.
    • Warning signs requiring medical attention:
    • Rapid weight gain (2–3 lb in 1 day, or 5 lb in 1 week), increasing shortness of breath, edema, persistent cough, loss of appetite, restless sleep, profound fatigue.

  • Pulmonary edema (acute HF complication)

    • Definition: Acute event where the left ventricle cannot handle an overload of blood volume, causing pressure increases in the pulmonary vasculature and fluid movement into interstitial spaces and alveoli.
    • Consequences: Hypoxemia.
    • Clinical manifestations: restlessness, anxiety, dyspnea, cool/clammy skin, cyanosis, weak and rapid pulse, cough with moist/noisy respirations, increased sputum production (sputum may be frothy and blood-tinged), decreased level of consciousness.

  • The nursing process perspective

    • The education and care strategies are framed within the nursing process for HF patients, including assessment, planning, implementation, and evaluation of interventions.

  • Quick reference: key numerical values and thresholds to remember

    • Fluid restriction: 2 L/day2\ \text{L/day}
    • Sodium restriction (diet): generally targeted around 2 g/day2\ \text{g/day} for HF management
    • BNP interpretation: BNP<100⇒no HF\text{BNP} < 100\Rightarrow \text{no HF}; BNP>400⇒HF present\text{BNP} > 400\Rightarrow \text{HF present}; BNP increases with worsening HF
    • Weight monitoring guidance (education): notify clinician for weight gain patterns such as 2–3 lb in 1 day or 5 lb in 1 week
    • Exercise guidelines: aim for approximately 30 minutes of moderate activity, most days, with warm-up and cool-down; stop for severe dyspnea or dizziness

  • Core takeaways for exam preparation

    • HF is a syndrome with left- and/or right-sided manifestations, influenced by risk factors such as CHD, hypertension, valvular disease, infections, chemo-related cardiotoxicity, and lifestyle factors.
    • Diagnosis hinges on imaging (echocardiography and EF), labs (electrolytes, BNP), and chest imaging, with BNP serving as a marker of severity.
    • Management is multi-faceted: pharmacologic (ACEIs, ARBs, ARNIs, beta-blockers, diuretics, digoxin, inotropes for decompensation), lifestyle modifications (sodium/fluid restriction, weight monitoring), device therapy (CRT), and supportive measures (oxygen, sleep management).
    • Patient education is crucial: adherence, diet, fluid management, activity pacing, weight monitoring, recognizing warning signs, and ensuring ongoing follow-up.

  • Appendix notes: knowledge application

    • Cardiac resynchronization therapy (CRT) details: reduces dyssynchrony by pacing both ventricles; can improve symptoms and exercise tolerance in selected HF patients.
    • Common nursing considerations with diuretics include monitoring electrolytes (K+, Na+, Mg2+), creatinine, uric acid, and signs of volume depletion or hypotension, and ensuring patients understand how to manage urinary frequency.
    • Understanding the differences between HF treatments (ACEI/ARB/ARNI, beta-blockers, diuretics, inotropes) helps in exam scenarios where a patient’s HF etiology or stage dictates specific therapy choices.